Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib in Advanced Solid Tumors and ALK-positive NSCLC
NCT01625234Phase 2Completed
- Sponsor
- Xcovery
- Start
- Jun 2012
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensartinib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), sponsored by Xcovery. Started Jun 2012; status: completed.
02
Drugs
ensartinib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01625234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625234.